Cas:100929-45-1 4-(N-[2,4-Diamino-6-pteridinylmethyl]amino)benzoic acid sodium salt manufacturer & supplier

Chemical Name:4-(N-[2,4-Diamino-6-pteridinylmethyl]amino)benzoic acid sodium salt

CAS.NO:100929-45-1

Synonyms:sodium,4-[(2,4-diaminopteridin-6-yl)methylamino]benzoate

Molecular Formula:C₁₄H₁₂N₇NaO₂

Molecular Weight:333.28100

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:681.8ºC at 760 mmHg

Density:N/A

Index of Refraction:

PSA:155.76000

Exact Mass:333.09500

LogP:0.79520

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like sodium,4-[(2,4-diaminopteridin-6-yl)methylamino]benzoate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,sodium,4-[(2,4-diaminopteridin-6-yl)methylamino]benzoate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,sodium,4-[(2,4-diaminopteridin-6-yl)methylamino]benzoate Use and application,sodium,4-[(2,4-diaminopteridin-6-yl)methylamino]benzoate technical grade,usp/ep/jp grade.

Related News: The memo denies the company made false statements to the FDA. In their complaint, employees said they were broadly concerned that quality control documents the FDA requires companies to maintain had been rewritten or fabricated. The employees did not specify whether these materials had been shown to the FDA. 4-(N-[2,4-Diamino-6-pteridinylmethyl]amino)benzoic acid sodium salt manufacturer At present, Teva can produce more than 300 generic drugs, and the API department has approximately 650 authorized patents and patent applications worldwide. It is also the generic drug company with the most challenges in patenting ParagraphIV in the world. 4-(N-[2,4-Diamino-6-pteridinylmethyl]amino)benzoic acid sodium salt supplier At present, Teva can produce more than 300 generic drugs, and the API department has approximately 650 authorized patents and patent applications worldwide. It is also the generic drug company with the most challenges in patenting ParagraphIV in the world. 4-(N-[2,4-Diamino-6-pteridinylmethyl]amino)benzoic acid sodium salt vendor The memo denies the company made false statements to the FDA. In their complaint, employees said they were broadly concerned that quality control documents the FDA requires companies to maintain had been rewritten or fabricated. The employees did not specify whether these materials had been shown to the FDA. 4-(N-[2,4-Diamino-6-pteridinylmethyl]amino)benzoic acid sodium salt factory Javier Valero-Elizondo, M.D., M.P.H., from the Houston Methodist DeBakey Heart and Vascular Center in Texas, and colleagues compared FT for individuals with ASCVD only, cancer only, both ASCVD and cancer, and neither ASCVD nor cancer using data from the National Health Interview Survey.